Hypertension May Reduce the Infection Risk but Increase the Severity of COVID-19: Based on the Current Data in China

Increasing evidence has shown an unusual relationship between hypertension and COVID-19, which may not be as simple as previously thought. The purpose of our study was to determine the association of hypertension with the onset and development of COVID-19. A meta-analysis was performed to summarize...

Full description

Saved in:
Bibliographic Details
Main Authors: Bo Li, Lu Zeng, Nengjun Sun, Yunhe Zhao, Faming Zhao, Hongjun Bian, Wei Yi, Jing Yang, Bin Li, Guohai Su
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:International Journal of Hypertension
Online Access:http://dx.doi.org/10.1155/2021/6594863
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850167473632968704
author Bo Li
Lu Zeng
Nengjun Sun
Yunhe Zhao
Faming Zhao
Hongjun Bian
Wei Yi
Jing Yang
Bin Li
Guohai Su
author_facet Bo Li
Lu Zeng
Nengjun Sun
Yunhe Zhao
Faming Zhao
Hongjun Bian
Wei Yi
Jing Yang
Bin Li
Guohai Su
author_sort Bo Li
collection DOAJ
description Increasing evidence has shown an unusual relationship between hypertension and COVID-19, which may not be as simple as previously thought. The purpose of our study was to determine the association of hypertension with the onset and development of COVID-19. A meta-analysis was performed to summarize the prevalence of hypertension in COVID-19 patients, as well as the usage of ACEIs/ARBs. Metaregression analyses were used to evaluate the association of hypertension with disease severity and mortality. PubMed and Google Scholar were searched for relevant studies. A total of 42 studies including 14138 patients were enrolled in the study. The proportion of hypertension in COVID-19 patients in China was 17.7% according to the enrolled studies, while it was 6.0% in a study containing 72314 confirmed cases, which are both much lower than in the general population. All of the data from the 11 provinces in China showed the same tendency. The proportions of hypertension were higher in severe/ICU patients and nonsurvivors than in nonsevere/ICU patients and survivors. The metaregression analyses suggested that both disease severity and risk of death were associated with the incidence of hypertension. A total of 27.6% of COVID-19 patients with hypertension received ACEI/ARB therapy. The proportion of deaths in COVID-19 patients with hypertension treated with ACEIs/ARBs was significantly lower than that in nonuse patients treated with ACEIs/ARBs. In conclusion, hypertension may reduce the infection risk of COVID-19 but increase the risk of developing worse clinical outcomes. The use of ACEIs/ARBs may benefit COVID-19 patients with hypertension.
format Article
id doaj-art-d7f9a1bd455a4d089cd06caff2faa2d2
institution OA Journals
issn 2090-0392
language English
publishDate 2021-01-01
publisher Wiley
record_format Article
series International Journal of Hypertension
spelling doaj-art-d7f9a1bd455a4d089cd06caff2faa2d22025-08-20T02:21:11ZengWileyInternational Journal of Hypertension2090-03922021-01-01202110.1155/2021/6594863Hypertension May Reduce the Infection Risk but Increase the Severity of COVID-19: Based on the Current Data in ChinaBo Li0Lu Zeng1Nengjun Sun2Yunhe Zhao3Faming Zhao4Hongjun Bian5Wei Yi6Jing Yang7Bin Li8Guohai Su9Department of CardiologyWeifang Medical UniversityDepartment of Medical AdministrationDepartment of CardiologyDepartment of Infectious DiseasesDepartments of Emergency MedicineDepartment of Intelligent Manufacturing TeachingBinzhou Medical UniversityDepartment of CardiologyDepartment of CardiologyIncreasing evidence has shown an unusual relationship between hypertension and COVID-19, which may not be as simple as previously thought. The purpose of our study was to determine the association of hypertension with the onset and development of COVID-19. A meta-analysis was performed to summarize the prevalence of hypertension in COVID-19 patients, as well as the usage of ACEIs/ARBs. Metaregression analyses were used to evaluate the association of hypertension with disease severity and mortality. PubMed and Google Scholar were searched for relevant studies. A total of 42 studies including 14138 patients were enrolled in the study. The proportion of hypertension in COVID-19 patients in China was 17.7% according to the enrolled studies, while it was 6.0% in a study containing 72314 confirmed cases, which are both much lower than in the general population. All of the data from the 11 provinces in China showed the same tendency. The proportions of hypertension were higher in severe/ICU patients and nonsurvivors than in nonsevere/ICU patients and survivors. The metaregression analyses suggested that both disease severity and risk of death were associated with the incidence of hypertension. A total of 27.6% of COVID-19 patients with hypertension received ACEI/ARB therapy. The proportion of deaths in COVID-19 patients with hypertension treated with ACEIs/ARBs was significantly lower than that in nonuse patients treated with ACEIs/ARBs. In conclusion, hypertension may reduce the infection risk of COVID-19 but increase the risk of developing worse clinical outcomes. The use of ACEIs/ARBs may benefit COVID-19 patients with hypertension.http://dx.doi.org/10.1155/2021/6594863
spellingShingle Bo Li
Lu Zeng
Nengjun Sun
Yunhe Zhao
Faming Zhao
Hongjun Bian
Wei Yi
Jing Yang
Bin Li
Guohai Su
Hypertension May Reduce the Infection Risk but Increase the Severity of COVID-19: Based on the Current Data in China
International Journal of Hypertension
title Hypertension May Reduce the Infection Risk but Increase the Severity of COVID-19: Based on the Current Data in China
title_full Hypertension May Reduce the Infection Risk but Increase the Severity of COVID-19: Based on the Current Data in China
title_fullStr Hypertension May Reduce the Infection Risk but Increase the Severity of COVID-19: Based on the Current Data in China
title_full_unstemmed Hypertension May Reduce the Infection Risk but Increase the Severity of COVID-19: Based on the Current Data in China
title_short Hypertension May Reduce the Infection Risk but Increase the Severity of COVID-19: Based on the Current Data in China
title_sort hypertension may reduce the infection risk but increase the severity of covid 19 based on the current data in china
url http://dx.doi.org/10.1155/2021/6594863
work_keys_str_mv AT boli hypertensionmayreducetheinfectionriskbutincreasetheseverityofcovid19basedonthecurrentdatainchina
AT luzeng hypertensionmayreducetheinfectionriskbutincreasetheseverityofcovid19basedonthecurrentdatainchina
AT nengjunsun hypertensionmayreducetheinfectionriskbutincreasetheseverityofcovid19basedonthecurrentdatainchina
AT yunhezhao hypertensionmayreducetheinfectionriskbutincreasetheseverityofcovid19basedonthecurrentdatainchina
AT famingzhao hypertensionmayreducetheinfectionriskbutincreasetheseverityofcovid19basedonthecurrentdatainchina
AT hongjunbian hypertensionmayreducetheinfectionriskbutincreasetheseverityofcovid19basedonthecurrentdatainchina
AT weiyi hypertensionmayreducetheinfectionriskbutincreasetheseverityofcovid19basedonthecurrentdatainchina
AT jingyang hypertensionmayreducetheinfectionriskbutincreasetheseverityofcovid19basedonthecurrentdatainchina
AT binli hypertensionmayreducetheinfectionriskbutincreasetheseverityofcovid19basedonthecurrentdatainchina
AT guohaisu hypertensionmayreducetheinfectionriskbutincreasetheseverityofcovid19basedonthecurrentdatainchina